Study guide
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests
Key Takeaways Explain This Topic AI
Normal pregnancy lowers serum creatinine (to about 0.4–0.6 mg/dL), raises alkaline phosphatase (from the placenta) and fibrinogen, and causes a mild leukocytosis, so non-pregnant reference ranges can mislead.
Nontreponemal tests (RPR, VDRL) track disease activity with titers but have biologic false positives, while treponemal tests (TP-PA, FTA-ABS, EIA) usually stay positive for life.
A urine protein-to-creatinine ratio of 0.3 mg/mg or higher (or 300 mg or more in 24 hours) defines significant proteinuria in pregnancy.
Annual fecal immunochemical testing (FIT) needs no dietary restriction; a single stool sample collected during a digital rectal exam is not adequate colorectal cancer screening.
A negative rapid COVID-19 antigen test in a symptomatic person should be repeated after 48 hours, while a NAAT (PCR) is the most sensitive test.
Last updated: October 2026
Interpreting Labs in Context
Reference ranges come from nonpregnant adults. Pregnancy, the menstrual cycle, hormonal contraception, and lactation change many values, and the exam often tests whether you can tell a physiologic change from disease.
Test Nonpregnant Adult Normal Pregnancy Clinical Pearl
Hemoglobin 12–16 g/dL Lower (anemia: <11 in the 1st and 3rd trimesters, <10.5 in the 2nd) Plasma volume rises more than red-cell mass
White blood cells 4,500–11,000/mcL Up to about 15,000 (higher in labor) Leukocytosis alone does not prove infection
Platelets 150,000–400,000/mcL Mildly lower Gestational thrombocytopenia is usually >100,000
Creatinine 0.6–1.1 mg/dL About 0.4–0.6 0.8 or higher warrants evaluation for renal impairment; >1.1 is a severe feature of preeclampsia
Alkaline phosphatase 30–120 U/L 2–4 times higher (placental) Not a liver marker in pregnancy
AST/ALT Normal Unchanged or slightly lower Elevation is abnormal (HELLP, cholestasis, hepatitis, acute fatty liver)
- Fibrinogen 200–400 mg/dL 400–600 mg/dL Below 200 in hemorrhage predicts severe bleeding
- TSH 0.4–4.0 mIU/L Lower in the first trimester (hCG effect) Use trimester-specific ranges
- Hematology and Coagulation
CBC and indices: MCV sorts anemia into microcytic, normocytic, and macrocytic types; RDW is high in iron deficiency and normal in thalassemia trait (see the anemia section).
Blood type and antibody screen: Done at the first visit in every pregnancy (see the Rh alloimmunization section).
Hemoglobin electrophoresis or HPLC: Sickle cell trait (HbAS, about 40% HbS), sickle cell disease (HbSS), HbC and HbE, and beta-thalassemia trait (HbA2 >3.5%) . Alpha-thalassemia trait shows normal electrophoresis and needs DNA testing . If the patient is a carrier, test the reproductive partner.
Coagulation studies:
PT/INR reflects the extrinsic pathway and is used to monitor warfarin and assess liver synthetic function.
aPTT reflects the intrinsic pathway and is used for unfractionated heparin monitoring; it is paradoxically prolonged by lupus anticoagulant , which causes clotting, not bleeding.
Von Willebrand panel (vWF antigen, ristocetin cofactor activity, factor VIII) for heavy menstrual bleeding since menarche.
D-dimer helps exclude VTE outside pregnancy but rises normally in pregnancy.
Chemistry, Diabetes, and Urine Studies
Comprehensive metabolic panel: Electrolytes, renal function, glucose, liver enzymes, albumin (lower in pregnancy), and calcium.
Lipid profile: Fasting is not required for most patients (see the dyslipidemia section).
Diabetes tests: Fasting glucose (126 mg/dL or higher diagnostic), 2-hour 75-g OGTT (200 or higher), and A1C (6.5% or higher). A1C is unreliable in pregnancy, after transfusion or hemorrhage, with hemoglobinopathies, and with iron deficiency or anemia; pregnancy uses the 50-g challenge followed by a 100-g OGTT, or the one-step 75-g OGTT.
Urinalysis: Leukocyte esterase and nitrites suggest UTI (nitrites need gram-negative organisms), protein, glucose (normal pregnancy can show mild glycosuria), ketones (fasting or hyperemesis), and blood.
Urine culture: 100,000 CFU/mL or more of a single organism in a clean-catch sample; lower counts can be significant in a symptomatic patient.
Proteinuria in pregnancy: A protein-to-creatinine ratio of 0.3 mg/mg or higher or 300 mg or more in 24 hours is significant; a dipstick of 2+ is used only when quantitative tests are unavailable.
Hormone Studies
Test Use Interpretation
hCG (quantitative) Pregnancy, ectopic, GTD Rises at least 35% every 48 hours in a viable early pregnancy; markedly high in molar pregnancy
FSH and estradiol POI, menopause, amenorrhea FSH >25 IU/L with at least 4 months of oligomenorrhea suggests POI; routine FSH is not needed to diagnose menopause after 45
Mid-luteal progesterone Ovulation >3 ng/mL confirms ovulation
Prolactin Amenorrhea, galactorrhea Repeat mild elevations fasting; check TSH and medications; very high levels suggest prolactinoma (pituitary MRI)
TSH and free T4 Thyroid Interpret with trimester-specific ranges in pregnancy
Total testosterone and DHEA-S Hyperandrogenism Testosterone >150–200 ng/dL or DHEA-S >700 mcg/dL raises concern for a tumor
- 17-hydroxyprogesterone Non-classic CAH Early-morning follicular-phase value <200 ng/dL makes it unlikely
- AMH Ovarian reserve; PCOS Low suggests diminished reserve; does not predict natural fertility
- Serologic Screening
Syphilis: Nontreponemal tests (RPR, VDRL) give titers that track activity and fall after treatment (a fourfold drop shows response), but have biologic false positives (pregnancy, lupus, antiphospholipid syndrome, viral infections). Treponemal tests (TP-PA, FTA-ABS, EIA/CIA) confirm infection and usually stay positive for life. Many labs use the reverse algorithm (treponemal test first).
HIV: Laboratory 4th-generation antigen/antibody test, then a differentiation assay; HIV RNA testing resolves discordant results or suspected acute infection.
Hepatitis: HBsAg (current infection), anti-HBs (immunity), anti-HBc (past or current exposure; IgM for acute); HCV antibody followed by HCV RNA to confirm active infection.
Immunity screening: Rubella IgG and varicella IgG.
CMV and toxoplasmosis: IgM can persist or be falsely positive; IgG avidity testing separates recent from past infection. Routine screening is not recommended.
HSV type-specific serology (glycoprotein G) identifies prior infection, but routine screening of the general population is not recommended, and low-positive HSV-2 results can be false positives that need confirmation.
Fecal, Vaginal, Throat, and Skin Tests
Fecal occult blood testing: FIT detects human hemoglobin, needs no dietary restriction, and is done annually at home; guaiac FOBT needs dietary limits and three samples. A positive stool test requires colonoscopy . A single in-office stool sample from a digital rectal exam is not adequate screening.
Vaginal microscopy and pH: Saline wet mount (clue cells, trichomonads, white blood cells), KOH (hyphae, whiff test), and pH; vaginitis NAAT panels improve accuracy.
STI testing: NAAT on a vaginal swab (preferred for women, including self-collected), first-catch urine (preferred for men), and rectal or pharyngeal swabs based on exposure.
Throat culture: Used as a backup after a negative rapid strep test in children, not adults; also for gonococcal pharyngitis (NAAT).
Skin and wound cultures: For purulent infections, to identify MRSA and guide antibiotics; KOH or fungal culture for suspected tinea or onychomycosis.
COVID-19 Testing
NAAT (PCR) is the most sensitive test. Antigen tests are less sensitive, so the FDA advises repeating a negative antigen test after 48 hours in a symptomatic person (and testing three times, 48 hours apart, after an exposure without symptoms). Pregnant patients with COVID-19 are at higher risk of severe illness and are eligible for antiviral treatment; check drug interactions with ritonavir-boosted nirmatrelvir.